Medication info
Polmin Sitagliptin Extended-Release Tablets 50/1000 mg (Sitagliptin Hydrochloride Monohydrate, Metformin Hydrochloride)

Polmin Sitagliptin Extended-Release Tablets 50/1000 mg (Sitagliptin Hydrochloride Monohydrate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Nokshim Pharmaceutical Co., Ltd.
Appearance
Bright green, oval-shaped, bilaterally convex extended-release film-coated tablets.
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202202010 · Approved 2022.05.13 · Insurance code 643606380

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dosage of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with food once daily, preferably in the evening, and the dosage should be increased gradually. To maintain the extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the medicine was incompletely dissolved and excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no previous experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dosage may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin treatment: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. - Patients who were receiving immediate-release tablets at a dose of 850 mg or 1000 mg twice daily based on their existing metformin dose may start at a dose of 2 tablets of this medicine 50/1000 mg extended-release tablet once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and existing dose. The dosage should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).

Ingredients

Manufacturer
Nokshim Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used for helping patients with type 2 diabetes control their blood sugar levels. It is primarily taken along with dietary therapy and exercise, with sitagliptin and metformin working together to effectively lower and regulate blood glucose levels. This helps patients who find it difficult to manage their blood sugar maintain a more stable blood sugar state. Therefore, this medicine is used for improving blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

In antidiabetic therapy, the dosage of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with food once daily, preferably in the evening, and the dosage should be increased gradually. To maintain the extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the medicine was incompletely dissolved and excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no previous experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dosage may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin treatment: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. - Patients who were receiving immediate-release tablets at a dose of 850 mg or 1000 mg twice daily based on their existing metformin dose may start at a dose of 2 tablets of this medicine 50/1000 mg extended-release tablet once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and existing dose. The dosage should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).

Precautions

This medication contains two components: sitagliptin and metformin. Sitagliptin can rarely cause allergic reactions, which in severe cases may lead to symptoms such as anaphylaxis or angioedema, and severe skin disorders such as Stevens-Johnson syndrome. Additionally, sitagliptin may pose a risk of causing acute pancreatitis, a serious pancreatic condition, thus patients should be closely monitored for symptoms of pancreatitis after taking this medication. Metformin can cause lactic acidosis, a rare but life-threatening metabolic reaction. This condition occurs due to the accumulation of lactate in the body, and in severe cases, it can lead to death. This medication should not be used in patients with significantly impaired kidney function, severe heart disease, acute infections or dehydration, liver dysfunction, women who are pregnant or breastfeeding, and in patients with certain metabolic diseases. Caution should be exercised during administration due to the potential for interactions with irregular meals, intense exercise, and other medications which may elevate risks of hypoglycemia or lactic acidosis. While taking this medication, regular monitoring of blood sugar, kidney function, liver function, and vitamin B12 levels is needed, and if any abnormal symptoms occur, immediate consultation with a doctor is advised. In particular, if symptoms such as sudden shortness of breath, muscle pain, weakness, abdominal pain, or changes in consciousness arise, the use of this medication should be stopped immediately and medical attention should be sought. Additionally, excessive alcohol consumption should be avoided while taking this medication, and dosages may be temporarily halted pre- and post-surgery under doctor's guidance. Be cautious about hypoglycemia symptoms, and if taken with other hypoglycemic agents or insulin, the risk of hypoglycemia may be increased, thus meticulous blood sugar management is required. Lastly, the safety and efficacy of this medication have not been well established in children, hence it is not recommended for individuals under the age of 18.

Side effects

  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 16 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • rash
  • urticaria
  • cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture and should be kept at room temperature between 1 to 30 degrees Celsius. Storing it this way helps maintain the medication's effectiveness for a longer duration.

Appearance and packaging

Appearance

Bright green, oval-shaped, bilaterally convex extended-release film-coated tablets.

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.